Incidence and significance of intraperitoneal anaerobic bacteria.
To amplify recent interest in anaerobic infections following abdominal disease, trauma, or surgery, 512 consecutive patients subjected to emergency celiotomy had both aerobic and anaerobic cultures taken of peritoneal fluid as well as all complicating wound and intra-abdominal infections. Average time between peritoneal entry of abscess drainage and specimen incubating under anaerobic conditions was less than two minutes. During 4 of the seven study months, patients had antibiotic therapy randomized, with clindaymcin or cephalothin being sole parenteral agents and given intravenously prior to operation and for 5 days thereafter. Results demonstrated that anaerobes uniformly contaminate the peritoneal cavity whenever distal or obstructed intestine has been perforated, irrespective of the cause. Although all but one of the 123 complicating wound and intra-abdominal infections were due solely or at least in part to aerobic pathogens, 2/3 of such infections also contained one or more different anaerobic species acting in synergism with the aerobes. No significant difference in incidence of postoperative infection or in infecting bacteria could be found with respect to antibiotic administered or etiology of perforation. Indeed, duration of bacterial exposure to atmospheric oxygen was the most critical factor influencing culture recoverability of anaerobic organisms, likelihood of ensuing wound or peritoneal sepsis participated in by an anaerobe, and success in control of established infections harboring anaerobes.
D000005:Abdomen / Q000382:microbiology / Q000601:surgery; D000332:Aerobiosis; D000388:Air; D000693:Anaerobiosis; D001064:Appendicitis / Q000382:microbiology; D001202:Ascitic Fluid / Q000382:microbiology*; D001419:Bacteria / Q000302:isolation & purification*; D001424:Bacterial Infections / Q000453:epidemiology; D002512:Cephalothin / Q000009:adverse effects / Q000627:therapeutic use; D002849:Chromatography, Gas; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use; D005845:Georgia; D006801:Humans; D007415:Intestinal Obstruction / Q000382:microbiology; D008660:Metabolism; D008826:Microbial Sensitivity Tests; D010529:Peritoneal Cavity / Q000382:microbiology; D010538:Peritonitis / Q000382:microbiology; D018805:Sepsis / Q000382:microbiology; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000453:epidemiology
D002981:Clindamycin; D002512:Cephalothin